New Drug Results with CAL101 for Lymphoma Patients

Dr. Brad Kahl at the UW Carbone Cancer Center discusses a new drug for lymphoma patients called CAL101. Patients on this medication feel no ill effect of taking this pill, and of the first 6 people to whom Dr. Kahl has given this agent to, all 6 of them have experienced some clinical benefit. These benefits include shrinkage of lymph nodes and tumor cells. When you look at the data all across the study from the other sites, 6 out of 7 mantle cell lymphoma patients responded to this drug, over half of the follicular patients responded to this drug, and a large percentage of patients with a disease called chronic lymphocytical leukemia have responded to this drug.

Category:

Science & Technology

Tags:

• Dr. Brad Kahl
• Carbone
• UW
• lymphoma
• CAL101
• cancer
• Calistoga
• tumor cells
• results
• drug

[ForwardLymphoma]

@purple8ball Thank you for your comment. We will be happy to help by directing you to Cancer Connect, a patient resource at the UW Carbone Cancer Center. You can email cancerconnect@uwcarbone.wisc.e­du or call 800-622-8922 (9:00 a.m. and 4:00 p.m. CST) to receive further assistance. Cancer Connect is staffed by skilled oncology nurses and health educators to provide you additional information. Forward Lymphoma is a fundraising initiative dedicated to lymphoma research.

[purple8ball]

I would love for my mom to see this Dr. !!!! This so much sounds like my mom's case who has CLL. She has had 3 different rounds of chemo in the past year and a very high dose of radiation which caused tumorlysis and we almost lost her twice. How can you become apart of this study?